Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Merdad Parsey
Age : 57
Public asset : 930,763 USD
Country of residence : Unknown
Linked companies : Gilead Sciences, Inc. - Arcus Biosciences, Inc.

Biography of Merdad Parsey 
Dr. Merdad V. Parsey is an Independent Director at Arcus Biosciences, Inc. and a Chief Medical Officer at Gilead Sciences, Inc. He is on the Board of Directors at Arcus Biosciences, Inc. and Sagimet Biosciences, Inc. Dr. Parsey was previously employed as a Senior Medical Director by Regeneron Pharmaceuticals, Inc., a Senior Director-Medical Group by Genentech, Inc., an Associate Medical Director by Merck & Co., Inc., a Director-Critical Care Medicine by New York University School of Medicine, a Member by Roche Group, and a Senior Medical Director by Sunovion Pharmaceuticals, Inc. He received his doctorate degree from the University of Maryland.


Current positions of Merdad Parsey 
Holdings of Merdad Parsey 
Merdad Parsey : Personal Network 
Most Read News 
07/12ELON MUSK : Musk tells SolarCity trial that Tesla would 'die' if he wasn't CEO
RE
07/15JAMIE DIMON : Analysis-JPMorgan hoards cash as Dimon expects rates to rise
RE
07/13RICHARD BRANSON : Virgin Galactic acknowledges Branson's pre-launch bike ride never happened
RE
07/20JEFF BEZOS : billionaire Bezos has successful suborbital jaunt
RE
07/13ELON MUSK : Musk defends timing of Tesla's $2.6 billion deal for SolarCity
RE
07/09ELON MUSK : Who controls Tesla?
RE
07/13BRUNELLO CUCINELLI : Italian luxury group Cucinelli raises 2021 sales forecast again
RE
07/22RYAN COHEN : Flush from Reddit rally, GameStop plots store revival
RE
07/18ALEXANDER NOVAK : Novak says Russia to raise oil output in H2
RE
07/20WILLIAM ACKMAN : Analysis-SPAC u-turn mars Ackman's hedge fund pivot
RE
More news


© 2021 People and Ownership :   
Merdad Parsey : Connections 


Latest news about Merdad Parsey 
06/28Gilead Submits NDA for Lenacapavir to U.S. FDA
DJ
05/21Inside the race to find a COVID-19 treatment pill
RE
05/21Inside the race to find a COVID-19 treatment pill
RE
03/25GILEAD SCIENCES : Gets EU Approval to Bring Breast-Cancer Drug to Market
DJ
03/12INSIDER TRENDS : Insider at Gilead Sciences Gets Share Award, Exercises Derivative Security, Makes Tax Sale with Portion
MT
02/04Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales
RE
2020INSIDER TRENDS : Gilead Sciences Insider Converts Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact
MT
More news